The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

International drug giant GSK plc is moving its vaccine R&D and infectious disease teams to Cambridge from Maryland, and plans to expand its footprint here.

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

The class action concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Continue reading your article with a WSJ ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Learn more about how GSK is harnessing the power of technology to improve outcomes for people with cancer.